Healthcare Sector
7 articlesVisitors can use the page to follow market updates, practical investor context and market sectors, review examples and see how nearby terms changes the way a product, rule, account or market signal should be interpreted.
AstraZeneca Drops on Reported Bristol Myers Talks
A reported $400 billion merger would unite two drug giants at a time when AstraZeneca is still growing and Bristol Myers faces patent pressure, raising questions about strategy, antitrust risk and U.S. market access
Eli Lilly's Soaring Stock Tests the 'Own, Don't Trade' Philosophy
Eli Lilly's stock has surged nearly 400% in five years, but with shares now above $1,150, investors face a key question: does the long-term case still hold, or is it time to rethink the classic buy-and-hold approach
State Street Health Care Select Sector SPDR ETF vs. First Trust NYSE Arca Biotechnology Index Fund: A Comparison
Healthcare ETFs XLV and FBT offer sharply different approaches-one broad and low-cost, the other biotech-focused and higher risk. See how their fees, returns, volatility, and holdings stack up before choosing where to invest
UnitedHealth's Profit Jump Masks Deeper Cost Pressures for 2026
UnitedHealth Group's latest earnings beat expectations, but rising medical costs and shrinking membership signal that higher profits are coming at a price for both the company and its customers
UBS Hikes Eli Lilly Target as Prescription Data Clouds Outlook
UBS raised its price target for Eli Lilly to $1,425, outpacing other Wall Street banks, but new prescription data and high expectations ahead of earnings add risk for investors holding LLY shares into August
Biotech Stocks Outpace Tech as M&A Wave Reshapes 2026 Market
Biotech stocks are leading the market in 2026, fueled by a surge in acquisitions and a shift in regulatory policy. Investors are weighing whether the rally can continue as valuations climb and deal activity accelerates
Ionis Pharmaceuticals Stock Plunges After Consecutive Drug Setbacks
Ionis Pharmaceuticals shares tumbled nearly 29% in two days after a failed heart drug trial and a partner’s exit from Huntington’s disease programs, raising questions about future growth and competition in the biotech sector